TechsoMed, a medical software innovator dedicated to enhancing clinical impact in ablation therapy, announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for its VisAble.IO software intended to assist physicians in planning liver ablation procedures, and confirming ablation zones, with the goal of increasing treatment precision.
Ablation therapy is a preferred minimally invasive treatment that uses extremely high or low temperatures to destroy abnormal tissue. However, insufficient image guidance precision and treatment control, lead to high risk of recurrence and complications, creating significant barriers to widespread adoption and limiting patients’ eligibility.
VisAble.IO is the first product to be released as part of TechsoMed’s full BioTrace solution, an end-to-end software solution for full visualisation and control for image-guided ablation therapy. By utilising AI-based technology, BioTrace leverages standard imaging—such as ultrasound along with computed tomography (CT) or magnetic resonance imaging (MRI) to provide visualisation of the full extent of the ablation zone in real-time, together with smart, personalised treatment planning and assessment tools, allowing physicians to provide their patients with optimised care.
VisAble.IO employs advanced computation and image registration to assist physicians in crucial steps of planning and assessing the ablation coverage of a liver tumour. Its key features include three-dimensional (3D) visualisation of the ablation target within a patient-specific anatomical view, overlay and position of virtual instruments and estimated ablation regions onto medical images and finally, a unique interactive 3D view of ablation margins and missed volumes to help users assess ablation target coverage immediately post procedure.
“There is a real need for a good and efficient assessment tool, and it can serve any physician performing thermal ablations” said Ryosuke Tateishi (University of Tokyo, Tokyo, Japan).
“We are excited to receive 510(k) clearance for our VisAble.IO solution and appreciate the relentless efforts of our entire team in achieving this milestone. This is a pivotal step forward in our journey of elevating ablation therapy into image guided ablation therapy and making it available for every patient everywhere,” said Yossi Abu, CEO and founder of TechsoMed. “The FDA’s validation of VisAble.IO’s safety and effectiveness not only reflects the exceptional quality of our product but also paves the way for significant commercial opportunities”.
The full BioTrace platform also includes the BioTrace.IO Lite software system, which is currently under review by the FDA through the de novo pathway, following the successful completion of a multicentre pivotal trial conducted in the USA. With its algorithm-powered technology, BioTrace.IO Lite will be the first software device to provide visualisation of the ablated area based on standard real-time ultrasound imaging.